


TheraPEAK[®] SfAAV[®] Medium



The Next Step in AAV Production

Gene therapy holds significant promise for the delivery of enduring treatments or even cures for previously untreatable diseases. The key to development of clinical tools for gene therapy is safe and precisely targeted delivery of exogenous genetic material into the cells of patients. Adeno Associated Virus (AAV) is a popular viral vector for this process because it is a non-replicating viral vector with large packaging capacity.

Spodoptera Fuigiperda (Sf9) cells have classically been used to produce large size proteins and large quantities of viruses and proteins. Due to their ability to grow at high densities in suspension culture, Sf9 cells have become a reliable host for AAV production.

To support the needs of the gene therapy market, Lonza has developed TheraPEAK® SfAAV® Medium. This chemically defined medium allows faster, stable and more consistent growth of Sf9 cells compared to tested competitor media. Faster growth allows for infection one day earlier and SfAAV promotes more extracellular AAV production, less lactate and less ammonium build-up than leading media on the market, creating a better environment for health AAV production.

Features and Benefits

- Chemically defined
- Non-animal origin
- Hydrolysate free
- GMP produced medium
- Enhanced cell growth
- Increased AAV production
- Easier downstream processing
- Drug Master File reference available

TheraPEAK® SfAAV® Medium is a high-performance, regulatory friendly medium that is your next step to expedite the time to market for safe, scalable and life-saving gene therapies. To learn how this product can support your next step in AAV production, visit:

www.lonza.com/Therapeak-SfAAV

Better Doubling Time Stability




Figure 1.

Sf9 cells have better and more stable doubling time over 45 passages in TheraPEAK[®] SfAAV[®] Medium (in dark purple) than in any tested competitor medium (in light purple) ensuring more consistent Sf9 cell performance over time thereby allowing the customer to plan production runs more accurately.

Faster Sf9 Growth




Figure 2.

ST9 cells grow faster in TheraPEAK® SfAAV® Medium (in dark purple) than in tested competitor media (in light purple) so customers are able to initiate baculovirus infections at optimal cell densities (~3x106 cells/mL) at least a day earlier than in tested competitor media.

GMP Quality

Quality and safety are crucial to allow reliable results in clinical processes and ultimately, protect patients' lives. Lonza is dedicated to providing high quality cell and gene therapy products for global customers via our TheraPEAK® Line of media and reagents. All TheraPEAK® Media are manufactured according to regulations for medical devices including 21 CFR Part 820. Our manufacturing sites are FDA registered with an ISO 13485 certified quality management system. GMP formulations for further manufacturing use do not contain gentamicin and phenol red.

Enhanced AAV Production




Figure 3.

Sf9 cells produce more rAAV2 in TheraPEAK® SfAAV® Medium (in dark purple) than in leading competitor medium (in light purple) in bioreactors. Data generated through external collaboration.

Place your order or contact us for further info

Cat. No.	Description	Size
BP12-945Q	TheraPEAK [®] SfAAV [®] Medium	1 L (bottle)

Contact us

North America

Customer Service: + 1 800 638 8174 (toll free) order.us@lonza.com Scientific Support: + 1 800 521 0390 (toll free) scientific.support@lonza.com

Europe

Customer Service: + 32 87 321 611 order.europe@lonza.com Scientific Support: + 32 87 321 611 scientific.support.eu@lonza.com

International

Contact your local Lonza Distributor Customer Service: + 1 301 898 7025 Fax: + 1 301 845 8291 scientific.support@lonza.com

Lonza Walkersville, Inc. - Walkersville, MD 21793

TheraPEAK® Media Products are GMP produced and intended for research or further manufacturing use only but not for direct therapeutic use in humans. TheraPEAK® Media Products are GMP produced and intended for research or further manufacturing use only but not for direct therapeutic use in humans. For research use only. Not for use in diagnostic procedures. All trademarks belong to Lonza, registered in USA, EU or CH or to third party owners and used only for informational purposes. The information contained herein is believed to be correct and corresponds to the latest state of scientific and technical knowledge. However, no warranty is made, either expressed or implied, regarding its accuracy or the results to be obtained from the use of such information and no warranty is expressed or implied concerning the use of these products. The buyer assumes all risks of use and/or handling. Any user must make his own determination and satisfy himself that the products supplied by Lonza Group Ltd or its affiliates and the information and recommendations given by Lonza Group Ltd or its affiliates are (i) suitable for intended process or purpose, (ii) in compliance with environmental, health and safety regulations, and (iii) will not infringe any third party's intellectual property rights. The user bears the sole responsibility for determining the existence of any such third party rights, as well as obtaining any necessary licenses. For more details: www.lonza.com/legal.

©2022 Lonza. All rights reserved.

bioscience.lonza.com www.lonza.com/therapeak-sfaav